Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06676072 · ClinicalTrials.gov registry record · NA
A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:
A NA study of Atrial Fibrillation (AF) and Atrial Arrhythmia, sponsored by Abbott Medical Devices.
- Active
- Registry status
- NA
- Development phase
- 188
- Enrollment target
- 20
- Study locations
NCT06676072: Active NA study of Atrial Fibrillation (AF) and Atrial Arrhythmia, sponsored by Abbott Medical Devices.
NCT06676072 is a NA study of Atrial Fibrillation (AF) and Atrial Arrhythmia that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 188 participants, below the 709-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06676072, a NA study of Atrial Fibrillation (AF) and Atrial Arrhythmia, is active but no longer recruiting, sponsored by Abbott Medical Devices.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 188 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this clinical study is to demonstrate that ablation with the TactiFlex SE Ablation catheter, in conjunction with a compatible pulsed field ablation (PFA) and/or radio frequency (RF) generator, is safe and effective for the treatment of symptomatic, recurrent, drug refractory paroxysmal atrial fibrillation (PAF).
Conditions Studied
Interventions
- DEVICE PFA Ablation catheter
Study Locations (20)
Florida
- HCA Florida Mercy Hospital - Miami
- AdventHealth Orlando - Orlando
- Tallahassee Research Institute - Tallahassee
Michigan
- University of Michigan Medical Center - Ann Arbor
- Henry Ford Providence Southfield Hospital - Southfield
New York
- NYU Langone Health - New York
- New York Presbyterian Hospital/Cornell University - New York
Arizona
- HonorHealth - Scottsdale
Arkansas
- Arkansas Heart Hospital - Little Rock
California
- Stanford University Medical Center - Stanford
Colorado
- South Denver Cardiology Associates PC - Littleton
Georgia
- Piedmont Athens Regional Medical Center - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2024-11-22 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
What the registry record for NCT06676072 still lists
NCT06676072 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 709-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (73% lower).
The record links to 4 conditions, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 1 intervention - of which PFA Ablation catheter is the first listed.
NCT06676072 names 20 study sites across 16 states, led by Florida, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT06676072 about?
NCT06676072 is a clinical study titled "A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:". The objective of this clinical study is to demonstrate that ablation with the TactiFlex SE Ablation catheter, in conjunction with a compatible pulsed field ablation (PFA) and/or radio frequency (RF) generator, is safe and effective for the treatment of symptomatic, recurrent, drug refractory paroxys...
What is the current status of trial NCT06676072?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 188 participants. The study started on 2024-11-22. Estimated completion is 2026-04-30.
What conditions does trial NCT06676072 study?
This clinical trial studies the following conditions: Atrial Fibrillation (AF), Atrial Arrhythmia, Paroxysmal AF, Drug Refractory Paroxysmal Atrial Fibrillation.
What interventions are being tested in trial NCT06676072?
The interventions under investigation include: PFA Ablation catheter (DEVICE).
Who is sponsoring clinical trial NCT06676072?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06676072 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation (AF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06676072's enrollment target sits among peer trials
188 14th of 17 higher than 4 of 17 other Atrial Fibrillation (AF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation (AF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Digitally Rendered Interventions And Knowledge To Limit Ethanol-Associated Atrial Fibrillation Severity
RECRUITING · NA
-
Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation
RECRUITING · NA
-
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
RECRUITING · NA
-
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
RECRUITING · NA
-
Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On Fibrillation
RECRUITING · NA
-
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI